Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Remedy Q3'26 preview: Control Resonant launch shows in the growth figures

REMEDYResearch27.10.2026, 09.05
Atte RiikolaAnalyst
Discuss
Download report (PDF)

Summary

  • Remedy's Q3 revenue is expected to have grown nearly 300% to 48 MEUR, primarily driven by the release of Control Resonant, which is forecasted to have generated 41.8 MEUR in self-published game sales.
  • Q3 EBITDA is projected to rise to 10.4 MEUR, although profitability is impacted by marketing and distribution costs under the self-publishing model, with adjusted EBIT forecasted at 1.0 MEUR.
  • Despite the successful launch of Control Resonant, which sold over one million copies, Remedy is unlikely to change its guidance for the year, although minor refinements could be made.
  • For the full year, revenue is expected to reach 125 MEUR and EBITDA 25.3 MEUR, supported by Control Resonant's strong sales performance and positive reviews.

This content is generated by AI. You can give feedback on it in the Inderes forum.

Translation: Original published in Finnish on 10/27/2026 at 7:00 am EET.

Remedy will publish its Q3 report on Tuesday, November 3, at 9:00 am EET. We will review the results in a live reaction broadcast starting at 8:55 am (in Finnish). We expect revenue to have multiplied and EBITDA to have turned clearly positive, driven by Control Resonant, released on September 24. With this preview, we lower our assumptions for game sales falling in Q3. This reflects previously overly front-loaded sales assumptions for the final days of September and the timing of physical copies shifting into October, which will only show up in Q4 sales. Our full-year estimate for Resonant sales (1.9 million copies) is unchanged for now, and we will naturally review our assumptions again with the Q3 report. Our focus in the report will be on any further detail on Control Resonant sales and Remedy’s subsequent plans for both Resonant and its other game projects. We make no changes to our Accumulate recommendation or EUR 23.0 target price for Remedy ahead of the Q3 report.

Control Resonant release drives strong revenue growth

We forecast Remedy’s Q3 revenue to have grown by nearly 300% to 48 MEUR (Q3'25: 12.2 MEUR). Growth is driven by the release of Control Resonant, which we expect to have generated the majority of the quarter’s revenue (our forecast for self-published game sales: 41.8 MEUR). We estimate that Control Resonant sold ~0.9 million copies in Q3 (prev. 1.1 million) at an average price of EUR 55. On October 15, Remedy announced that the game had passed one million copies sold. Beyond self-published game sales, we expect revenue to include development fees of 5.0 MEUR, primarily from Max Payne 1&2 Remake. We expect royalty revenue of 1.2 MEUR, mostly from Alan Wake 2.

Resonant’s impact should also start to show in EBITDA

We forecast Remedy’s Q3 EBITDA to have jumped to 10.4 MEUR (Q3'25: 0.7 MEUR) on strong revenue growth. Considerable uncertainty surrounds the exact earnings for the quarter, however, as under the self-publishing model Remedy bears marketing and distribution costs itself, which weighs on profitability in the short term. Visibility into the scale of marketing spend is limited. Amortization of capitalized development costs also begins with the game’s release, which we expect to lift total depreciation and amortization for the quarter to 9.4 MEUR. We therefore forecast adjusted EBIT of only 1.0 MEUR. The scale and timing of depreciation and amortization are also uncertain. Cash flow may remain somewhat sluggish in Q3, as initial Resonant sales proceeds across the various console and PC platforms were presumably only paid out to Remedy in Q4.

Guidance is likely to remain unchanged, although minor refinements could be made

For this year, Remedy guides for revenue (2025: 60 MEUR) and EBITDA (2025: 11.3 MEUR) growth. Following the successful release of Control Resonant, meeting the current guidance is virtually certain. Some uncertainty naturally remains over game sales for the rest of the year, but in principle, Remedy could raise its guidance. We consider this rather unlikely, however. For full-year 2026, we expect revenue to rise to 125 MEUR and EBITDA to 25.3 MEUR, driven by Control Resonant. The game passed one million copies sold in ~3 weeks, making it Remedy’s fastest-selling game to date. In our view, this provides an excellent foundation for a long sales tail, especially given the strong reviews from players and critics alike.

Remedy Entertainment is a game developer. Its operations are primarily focused on the development of action games, with a particular focus on 3D technology. Examples of games that the company has developed include several different versions of Alan Wake, Max Payne, and Control. Remedy also develops its own game engine and tooling technology that powers many of its games. The company was founded in 1995 and is headquartered in Espoo, Finland.

Read more on company page

Key Estimate Figures26.10

202526e27e
Revenue59.5125.2121.7
growth-%17.5 %110.4 %-2.8 %
EBIT (adj.)-14.95.015.0
EBIT-% (adj.)-25.0 %4.0 %12.3 %
EPS (adj.)-0.960.250.86
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.61.317.6
EV/EBITDA17.27.46.3

Forum discussions

Max Payne 1 (2001) sold 2.75M copies within 10 months of its PC (and 6 months of its console) launch (5/2002). Below is Take-Two’s IR release...
1 hour ago
5
Resonant was fairly reasonably priced, which is indeed an excellent thing. I would believe that in terms of resource requirements, AW3 will ...
2 hours ago
by Relaaja
3
Atte isn’t my responsibility; I said that according to my own data, we’re landing at 1.9m copies—you can leave Atte out of it if that makes ...
2 hours ago
by Shamalamadingstock
0
By the way, is there any estimate on how big of a franchise Max Payne is, or how much the first game sold back in the day? I might have nostalgia...
2 hours ago
by supremegod
0
Valid criticism. However, I’m not quite as pessimistic about current or upcoming games as @Relaaja In my opinion, despite being a slight disappointmen...
2 hours ago
3
How relevant are these “quite good sales” if investors are left with nothing to show for it? Explain, then, how that growing fan base is showing...
2 hours ago
by Relaaja
0
I would argue that the other games are actually selling quite well—nothing explosive, but if you look at PSNProfiles, for instance, they’re ...
3 hours ago
by Shamalamadingstock
11